PemBla: Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC)
PEMBLA is a parallel group, open label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in the treatment of non-muscle invasive bladder cancer.
This single-institution safety run-in phase will identify a tolerable dose of intravesical pembrolizumab using a within-patient dose escalation schedule. This tolerable dose will be taken forward into the phase II randomised portion of the study for the intravesical treatment arm. The phase II portion of the study will expand recruitment to more centres and look at the efficacy and safety of intravenous and intravesical delivery modalities of pembrolizumab to the bladder in 30 patients.
Other clinical research
hyperthermic mitomycin treatment for bladder carcinoma: An Observational cohort study
This observational cohort study follows 97 people with high-risk non-muscle invasive urothelial carcinoma (bladder cancer). These people are given a well-established chemotherapy drug, mitomycin C. Unlike the standard protocol, the drug is administered with heat, which may improve how well the drug penetrates the cancer.
The study will follow the patients and see how they respond to the new treatment protocol. It will look for any patient characteristics that can predict that response. The Nuffield Department of Surgical Sciences' SITU is running this study.